The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 14, 2025
Filed:
Sep. 09, 2019
Applicant:
Legend Biotech Ireland Limited, Dublin, IE;
Inventors:
Yafeng Zhang, Jiangsu, CN;
Tailan Zhan, Jiangsu, CN;
Fei Sun, Jiangsu, CN;
Jian Liu, Jiangsu, CN;
Qing Zhang, Jiangsu, CN;
Shu Wu, Jiangsu, CN;
Assignee:
Legend Biotech Ireland Limited, Dublin, IE;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2005.12); A61K 35/17 (2014.12); A61K 40/11 (2024.12); A61K 40/31 (2024.12); A61K 40/42 (2024.12); C07K 14/705 (2005.12); C07K 14/725 (2005.12); C07K 16/28 (2005.12); C12N 5/0783 (2009.12); A61K 39/00 (2005.12);
U.S. Cl.
CPC ...
C07K 16/2803 (2012.12); A61K 35/17 (2012.12); A61K 40/11 (2024.12); A61K 40/31 (2024.12); A61K 40/4202 (2024.12); A61K 40/4204 (2024.12); A61K 40/421 (2024.12); A61K 40/4221 (2024.12); A61K 40/4224 (2024.12); A61P 35/00 (2017.12); C07K 14/7051 (2012.12); C07K 14/70578 (2012.12); C07K 16/2851 (2012.12); C07K 16/2866 (2012.12); C12N 5/0636 (2012.12); A61K 2039/505 (2012.12); A61K 2239/29 (2023.04); A61K 2239/31 (2023.04); A61K 2239/38 (2023.04); A61K 2239/48 (2023.04); C07K 2317/31 (2012.12); C07K 2317/565 (2012.12); C07K 2317/569 (2012.12); C07K 2317/92 (2012.12); C07K 2319/02 (2012.12); C07K 2319/03 (2012.12); C12N 2510/00 (2012.12);
Abstract
The present application provides single-domain antibodies targeting CD33 and constructs thereof, including chimeric receptors, immune effector cell engagers and immunoconjugates. Further provided are engineered immune cells (such as T cells) comprising an anti-CD33 chimeric receptor and optionally a second chimeric receptor targeting a second antigen or epitope. Pharmaceutical compositions, kits and methods of treating cancer are also provided.